Basic safety assessments indicated that gastrointestinal adverse occasions, mostly nausea and diarrhea, had been dose-dependent but usually mild and transient. These findings proven the therapeutic window and knowledgeable dose choice for subsequent Stage 3 trials.Renal security is equally reassuring. Throughout Stage one–3 trials, treatment with